Home
Home About Us Our Technology News + Media Investor Relations Contact Us
 
Company Press Releases Publications
 

Company Press Releases

9.15.16
CytoSorbents Sponsors Sepsis Heroes Gala in Honor of World Sepsis Day


9.12.16
Terumo and CytoSorbents Announce Strategic Partnership


9.8.16
CytoSorbents Advances War on Sepsis with Development of CytoSorb-XL


9.7.16
CytoSorbents to Present at 2016 Rodman & Renshaw Global Conference


8.9.16
CytoSorbents Achieves 4th Consecutive Quarter of Record CytoSorb Sales


8.8.16
CytoSorbents Awarded $650K in SBIR contracts to for Potassium Binder Development


8.2.16
CytoSorbents to Report Q2 2016 Operating and Financial Results


7.13.16
Medial and Meditrade Bring CytoSorb to Hungary, Czech Republic, Slovakia and Poland


7.6.16
CytoSorbents To Presents at Cantor Fitzgerald Healthcare Conference


7.1.16
CytoSorbents Closes $10M Debt Financing with Bridge Bank


6.22.16
CytoSorbents Awarded $150K Universal Plasma Phase I STTR


6.13.16
CytoSorbents and Palex Bring CytoSorb to Spain and Portugal


6.1.16
Fresenius Initiates CytoSorb Sales in France, Poland, and Scandinavia


5.27.16
CytoSorbents: DSMB Recommends Continuation of REFRESH I Trial


5.17.16
CytoSorb Achieves Final Product Registration in Russia


5.9.16
CytoSorbents Continues Strong Growth in Q1 2016


5.6.16
CytoSorbents Establishes Swiss Subsidiary


5.2.16
CytoSorbents to Announce Q1 2016 Results


4.6.16
CytoSorbents to Present at 15th Needham Healthcare Conference


3.25.16
CytoSorbents Awarded $150K Phase I SBIR for Mycotoxin Removal


3.16.16
CytoSorbents Reports Successful Third International CytoSorb Users Meeting


3.14.16
CytoSorbents Hosts 3rd International CytoSorb Users Meeting at ISICEM 2016


3.9.16
CytoSorbents Reports Record Q4 and Full Year 2015 Revenue


3.2.16
CytoSorbents to Report Fiscal 2015 Operating and Financial Results


2.26.16
Data Presented on First CytoSorb® Investigator-Initiated Septic Shock Study


2.18.16
CytoSorbents to Exhibit at the 45th Society of Critical Care Medicine Congress


2.16.16
CytoSorbents Announces 26th Symposium for Intensive Medicine and Intensive Care Agenda in Bremen, Germany


2.4.16
CytoSorbents to Present at Source Capital Group's 2016 Disruptive Growth & Healthcare Conference


2.1.16
CytoSorbents Receives $325,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program


1.28.16
CytoSorbents to Present at the 18th Annual BIO CEO & Investor Conference


1.21.16
CytoSorbents Appoints Dr. Volker Humbert as Senior Manager of Clinical Affairs


1.11.16
CytoSorbents 2016 - Driving Toward the Inflection Point


1.4.16
CytoSorbents To Present at Biotech Showcase 2016


12.21.15
CytoSorbents Issues EAP Update


12.15.15
CytoSorbents Expands Distribution of CytoSorb® to Vietnam


12.9.15
CytoSorbents to Ring Opening Bell to Celebrate One Year NASDAQ Anniversary


12.1.15
CytoSorbents to Participate in Upcoming Investor Conferences


11.13.15
CytoSorbents Accelerates Growth in Q3 2015


11.9.15
CytoSorbents To Meet With Investors at Brean Capital Life Sciences Summit and Stifel 2015 Healthcare Conference


11.6.15
CytoSorbents to Report Q3 2015 Operating and Financial Results


10.27.15
CytoSorbents To Advance HemoDefend™ Towards Commercialization with $1.5 Million Phase II SBIR Contract from NHLBI/NIH


10.5.15
CytoSorbents Reports CytoSorb® Usage Grows to 8,000+ Human Treatments at Successful Second International Users Meeting


9.30.15
CytoSorbents Ready for Second International CytoSorb® Users Meeting, ESICM and EACTS Conferences


9.14.15
World Sepsis Day 2015: CytoSorbents Sponsors the SepsisUpdate 2015 Congress, Hugo Schottmüller Prize, and Sepsis Heroes Ceremony


9.2.15
CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference


8.13.15
CytoSorbents Reports Steady Growth in Q2 2015


8.10.15
Saudi Food and Drug Authority Approves CytoSorb®


8.6.15
CytoSorbents to Report Q2 2015 Operating and Financial Results


7.23.15
CytoSorbents and TekMed Collaborate to Distribute CytoSorb® in Australia and New Zealand


7.15.15
Veteran Healthcare Analyst Michael G. Bator Joins CytoSorbents Board of Directors


5.26.15
CytoSorbents to Present at the LD Micro Invitational on June 1st


5.19.15
CytoSorbents and Alphamedix Team To Introduce CytoSorb® to Israel


5.11.15
CytoSorbents Reports 24% Year-over-Year Increase in CytoSorb® Sales in First Quarter 2015


5.4.15
CytoSorbents to Report Q1 2015 Operating and Financial Results


4.27.15
CytoSorbents Appoints Dr. Joerg Scheier as European Medical Director


4.24.15
CytoSorbents Issues Letter to Shareholders


4.14.15
CytoSorbents to Present at the 14th Annual Needham Healthcare Conference


4.7.15
CytoSorbents Issues Responses to Frequently Asked Questions


3.31.15
CytoSorbents Reports Record 2014 Revenue


3.24.15
CytoSorbents to Report Fiscal 2014 Operating and Financial Results


3.13.15
CytoSorbents Plans Robust Agenda at ISICEM 2015


3.11.15
CytoSorbents Launches New International CytoSorb® Therapy Product Website


2.2.15
CytoSorbents Announces FDA Approval to Commence Initial U.S. Cardiac Surgery Study


1.30.15
CytoSorbents And Aferetica Introduce CytoSorb® to Italy


1.23.15
CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program


1.14.15
CytoSorbents Announces Closing of Public Offering


1.7.15
CytoSorbents To Present at OneMedForum 2015 and Exhibit at the 44th Society of Critical Care Medicine Congress


12.30.14
CytoSorbents Submits IDE Application to FDA for U.S. CytoSorb® Cardiac Surgery Trial


12.23.14
CytoSorbents Corporation Begins NASDAQ Trading Today


12.22.14
CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development


12.18.14
CytoSorbents Receives NASDAQ Listing Approval


12.15.14
CytoSorbents Announces Strategic Partnership with Fresenius Medical Care


12.10.14
Prince William, Duke of Cambridge, Presents Award to CytoSorbents


12.10.14
Recent CytoSorb® Case Reports Highlight its Use to Help Save the Lives of Critically-Ill Patients


12.5.14
CytoSorbents Reports Temporary Change of Stock Trading Symbol


12.5.14
CytoSorbents Teams with Smart Medical Solutions to Distribute CytoSorb® in Romania and Moldova


11.26.14
CytoSorbents to Host Second CytoSorb® Users Meeting and Symposium at the DIVI Critical Care Congress


11.21.14
CytoSorbents Wins Beacon of Light Award


11.14.14
CytoSorbents Announces Appointment of New Board Director


11.12.14
CytoSorbents Achieves First $1M in Quarterly CytoSorb Sales in Q3 2014


11.10.14
CytoSorbents Announces Initial Partnership with a Leading Global Cardiac Surgery Company


11.6.14
CytoSorbents Issues Shareholder Update Letter on Consent Solicitation Statement and Up-Listing Plans


11.5.14
CytoSorbents to Report Q3 2014 Operating and Financial Results


11.3.14
Biocon Expands its Strategic Partnership with CytoSorbents for CytoSorb® to Treat SIRS and Cardiac Surgery Patients


10.14.14
Preliminary Q3 2014 Report: CytoSorbents Achieves Its First Quarter of Approximately $1M in CytoSorb® Sales and Provides Up-listing Update


10.10.14
CytoSorbents Wins 2014 GREAT Tech Award In Health


10.3.14
CytoSorbents Launches International CytoSorb® Treatment Registry


9.18.14
CytoSorbents Proudly Sponsors World Sepsis Day 2014, Celebration of Sepsis Heroes, and the Roger Bone Award


9.9.14
CytoSorbents Announces U.S. Cardiac Surgery Advisory Board


9.5.14
In Memoriam: Joseph Rubin (1938-2014) - CytoSorbents Co-founder and Board Director


9.3.14
CytoSorbents to Present at the 2014 Rodman & Renshaw Annual Global Investment Conference


8.12.14
CytoSorbents Records Another Solid Quarter of Growth in Q2 2014


8.6.14
CytoSorbents to Report Q2 2014 Operating and Financial Results


8.5.14
CytoSorbents Expands Distribution to Taiwan with Hemoscien Corporation


7.15.14
First Publication Using CytoSorb® Therapy During Cardiac Surgery


7.9.14
CytoSorbents Consolidates SEC and International Legal Counsel with DLA Piper


5.14.14
CytoSorbents Reports Strong Growth in Q1 2014


5.8.14
CytoSorbents to Report Q1 2014 Operating and Financial Results


4.8.14
CytoSorbents Expands Distribution to the Vast Middle Eastern Market of Saudi Arabia, United Arab Emirates, and Other GCC Countries with Techno Orbits


4.3.14
CytoSorbents to Present at the 13th Annual Needham Healthcare Conference


3.31.14
CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue


3.25.14
CytoSorbents to Report Fiscal 2013 Operating and Financial Results


3.13.14
CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014


3.7.14
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering


2.18.14
CytoSorbents Receives $458,000 in Non-Dilutive Funding From the New Jersey Technology Business Tax Certificate Transfer Program


2.10.14
CytoSorbents and University of Pennsylvania Vet School Collaborate to Expand CytoSorb® Research in Cancer Immunotherapy


2.5.14
CytoSorbents to Exhibit at the 43rd Annual Meeting of the German Society for Thoracic, Heart and Vascular Surgery


1.27.14
U.S. House of Representatives Rush Holt Awards CytoSorbents Export Achievement Award


1.15.14
CytoSorbents 2013 - The Rise of an Emerging Critical Care Immunotherapy Company


1.7.14
CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014


12.31.13
CytoSorbents Provides Clinical Update on CytoSorb Dosing Study


12.16.13
CytoSorbents Reports on Successful DIVI 2013 Conference


11.12.13
CytoSorbents Teams With INTENSIVMED for CytoSorb® Distribution in Russia


11.6.13
CytoSorbents Achieves Strong Third Quarter 2013 Revenue Growth


10.30.13
CytoSorbents Expands CytoSorb E.U. Distribution With WMC in the Netherlands


10.22.13
CytoSorbents to Report Third Quarter Fiscal 2013 Operating and Financial Results


9.13.13
Biocon Partners With CytoSorbents to Market CytoSorb® - A 'First-in-Class' Therapy for Sepsis Management


9.12.13
Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day


9.9.13
CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend™


8.28.13
CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference


8.21.13
CytoSorbents Expands CytoSorb® Dosing Study to Eight Clinical Trial Sites


8.14.13
CytoSorbents to Host Shareholder Update Conference on Wednesday, August 21st at 4:15 p.m. Eastern


8.14.13
CytoSorbents Provides Corporate Update and Reports Financial Results for the Period Ended June 30, 2013


7.26.13
CytoSorbents Selected to Present on HemoDefend™ at the Military Health System Research Symposium


7.8.13
CytoSorbents Appoints Dr. Rainer Kosanke as European Director of Scientific Affairs


6.27.13
CytoSorbents Announces Start of $1M US Army Phase II SBIR Contract and Closing of Additional Funding


6.17.13
CytoSorbents Announces FDA Approved US Air Force Funded Human Trauma Pilot Study for Rhabdomyolysis


6.13.13
CytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb® With Hitit Medical Systems in Turkey


5.16.13
CytoSorbents Reports 2013 First Quarter Financial Results


5.13.13
Kathleen P. Bloch Appointed as Chief Financial Officer of CytoSorbents


5.6.13
CytoSorbents Enters Into Exclusive Distribution Agreement for CytoSorb® With L.IN.C. Medical Systems in the United Kingdom and Ireland


5.1.13
CytoSorbents Provides Exclusive Interview with medGadget


4.15.13
CytoSorbents Appoints Christopher Cramer as Vice President of Business Development


4.11.13
CytoSorbents Awarded Additional Phase I Option on US Army SBIR Trauma Contract


4.8.13
CytoSorbents Announces Trauma Advisory Board


4.3.13
CytoSorbents Provides Corporate Update and Reports 2012 Year End Financial Results


3.26.13
CytoSorbents Provides Update on ISICEM 2013 Critical Care Conference


3.13.13
CytoSorbents to Exhibit at the ISICEM 2013 Critical Care Conference


3.5.13
CytoSorbents to Present at the Long Island Capital Alliance Health Care Capital Forum on March 8, 2013


2.8.13
CytoSorbents Appoints Ronald Berger as Interim Chief Financial Officer


1.29.13
CytoSorbents Receives Approximately $400,000 in Non-Dilutive Capital from the Sale of Net Operating Loss Carryovers


1.9.13
CytoSorbents 2012 End of Year Shareholder Letter


1.4.13
CytoSorbents to Present at the OneMedForum 2013 Finance Conference


11.30.12
CytoSorbents Appoints Thomas Bocchino as Chief Financial Officer


11.26.12
CytoSorbents Clarifies Q3 2012 Earnings Press Release


11.21.12
CytoSorbents Updates Corporate Progress and Third Quarter 2012 Financial Results


11.16.12
CytoSorbents Corporation Filing of 10-Q Delayed Due to Superstorm Sandy


9.27.12
CytoSorbents Continues to Expand Market Awareness of Its Technologies


9.24.12
US Army Grants CytoSorbents $1 Million Phase II SBIR Trauma and Burn Injury Award


9.7.12
CytoSorbents Sponsors the German Sepsis Society and Sepsis Heroes in Honor of World Sepsis Day


9.5.12
CytoSorbents To Present at Rodman & Renshaw 2012 Global Investment Conference


8.13.12
CytoSorbents Reports Corporate Update and Second Quarter 2012 Financial Results


8.9.12
CytoSorbents to Present and Exhibit at the Military Health System Research Symposium


8.6.12
DARPA Awards $3.8 Million Contract to CytoSorbents Corporation


7.25.12
Brean Murray Initiates Coverage with "Buy" Rating


6.29.12
Improvement in Heart Function in Organ Donor Animal Model Using CytoSorb® Highlighted at the Western Thoracic Surgical Association Meeting


6.20.12
CytoSorbents Appoints Dr. Christian Steiner as VP of Sales and Marketing and Hires Core Sales Force That Marks the Official Launch of CytoSorb® in Germany


6.20.12
CytoSorbents Announces Departure of CFO David Lamadrid


6.14.12
CytoSorbents to Present at the Marcum MicroCap Conference


6.5.12
Zacks Small Cap Research Initiates CytoSorbents with Outperform Rating


5.20.12
CytoSorbents Publishes Responses to Frequently Asked Questions - May 2012


5.15.12
CytoSorbents Reports Corporate Update and First Quarter 2012 Financial Results


5.11.12
Dr. Phillip Chan Named Finalist for Ernst & Young Entrepreneur of the Year® 2012 Award in New Jersey


5.08.12
CytoSorbents to Present at Frankfurt MedTech Investor Forum


4.19.12
CytoSorbents Receives European Trademark for CytoSorb®


4.09.12
CytoSorbents Corporation Establishes European Subsidiary


3.31.12
CytoSorbents Corporation Reports Full Year 2011 Financial Results and Corporate Update


3.07.12
CytoSorbents to Exhibit and Host Research Symposium at Major International Critical Care Conference


2.13.12
CytoSorbents Strengthens Balance Sheet Through Convertible Note


2.07.12
CytoSorbents to Exhibit at the 2012 Symposium of Intensive Medicine and Intensive Care


1.11.12
CytoSorbents 2011 End of Year Shareholder Letter


12.14.11
CytoSorbents Awarded US Army SBIR Trauma Grant


12.09.11
CytoSorbents Announces Purchase Agreement for up to $8.5 Million With Lincoln Park Capital


11.15.11
CytoSorbents Corporation Reports Third Quarter 2011 Financial Results and Corporate Update


10.25.11
CytoSorbents Corporation to Present at the IN3 Medical Device Summit


10.17.11
CytoSorbents Corporation Launches HemoDefend Purification Technology Platform for Blood Transfusion Applications at the AABB Conference CTTXPO Exhibition


9.23.11
CytoSorbents Corporation to Exhibit at the European Society of Intensive Care Medicine Congress in Berlin and at the AdvaMed Conference in Washington D.C.


9.13.11
CytoSorbents Announces New Statistical Analysis and Confirms Statistical Significance in 28-Day Mortality


9.8.11
CytoSorbents Corporation to Present at the Rodman & Renshaw Global Investment Conference


9.7.11
CytoSorbents Corporation Announces Additional Data From European Sepsis Trial


9.1.11
CytoSorbents Corporation to Exhibit at the German Sepsis Society International Congress


8.16.11
CytoSorbents Corporation Reports Second Quarter 2011 Financial Results


8.4.11
CytoSorbents Corporation to Exhibit at the Advanced Technology Applications for Combat Casualty Care Conference


6.6.11
CytoSorbents Corporation Releases Shareholder Letter


3.31.11
CytoSorbents Corporation Achieves European Union Regulatory Approval for CytoSorb™


2.22.11
CytoSorbents Closes Convertible Note With Additional $1.25 Million Raised


02.17.11
CytoSorbents Corporation Broadens Its Intellectual Property Portfolio


12.30.10
CytoSorbents Corporation to Present at the OneMedForum 2011 Finance Conference


11.17.10
CytoSorbents Corporation Reports Third Quarter 2010 Financial Results


11.2.10
CytoSorbents Corporation Awarded $488,958 Grant from the Federal Qualifying Therapeutic Discovery Project Program


09.27.10
CytoSorbents Corporation Achieves ISO 13485 Certification


09.09.10
CytoSorbents Corporation to Present at the Rodman & Renshaw Global Investment Conference


09.01.10
CytoSorbents' Chief Financial Officer is named a finalist for '2010 CFO of the Year' award by NJBIZ


08.19.10
CytoSorbents Corporation Reports Second Quarter 2010 Financial Results


08.11.10
CytoSorbents Corporation to Present Today at the Emerging Medical Technologies Spotlight Online Conference


07.26.10
CytoSorbents Corporation to Exhibit at the Force Health Protection Conference and ATACCC


06.08.10
CytoSorbents Corporation to Present at the In3 East Medical Device Conference


05.24.10
CytoSorbents Corporation to Present at BioNJ BioPartnering Conference


05.17.10
CytoSorbents Corporation Reports First Quarter 2010 Financial Results


05.10.10
Cytosorbents Corporation Enters Into Funding Agreement


05.06.10
MedaSorb Technologies Announces Company Name Change to CytoSorbents Corporation


04.12.10
MedaSorb Technologies Corporation Reports Full Year 2009 Financial Results


02.17.10
MedaSorb Technologies Corporation Improves Cash Position and Hits Midway Point in Study Enrollment


01.11.10
MedaSorb Technologies Corporation to Present at the Biotech Showcase™ 2010


11.13.09
MedaSorb Technologies Corporation Provides Clinical Update


11.13.09
MedaSorb Technologies Corporation Announces Q3 2009 Results and Files Form 10-Q, Quarterly Report


8.18.09
MedaSorb Technologies Corporation to Present at the Rodman & Renshaw Global Investment Conference


7.16.09
MedaSorb and CytoSorbents CEO Featured in Interviews by The Wall Street Transcript and CEO-CFO Interviews


5.06.09
CytoSorbents, Inc. Comments on CytoSorb(TM) and the Swine Flu Outbreak


3.30.09
CytoSorbents, Inc. Recognized as "Company Most Likely to Succeed" at the 2009 New Jersey Venture Conference and Provides Clinical Update


2.03.09
MedaSorb Technologies Corporation Improves Balance Sheet


1.9.09
MedaSorb Technologies Corporation Announces Management Changes


August 2008
Letter To Our Shareholders


1.4.07
MedaSorb Announces IDE Filing with the FDA



11.3.06
MedaSorb Technologies Corporation Files New Patent Application

10.27.06
MedaSorb Technologies Adds Strategic Technology Patent


9.19.06
MedaSorb Announces That They Intend to File Investigational Device Exemption With the FDA

8.7.06
MedaSorb Technologies to Begin Trading under the Symbol MSBT


7.25.06
Gilder Enterprises, Inc. Acquires MedaSorb Corporation and Raises $5.25 Million




 
Home | Career Opportunities | Contact Us
© 2016 CytoSorbents Corporation All Rights Reserved